Skip to content
Sign in
StableHealthReported 2026-11-19 01:10

Ten63 Therapeutics Launches BEYOND-Alpha Program with Chugai Pharmaceutical

Ten63 Therapeutics launched BEYOND-Alpha, an early adopter program for its BEYOND computational drug design platform, with Chugai Pharmaceutical as the first participant.

Why it matters. Pharmaceutical companies can now scale AI-driven drug discovery efforts, potentially accelerating the development of new treatments.

01

Who and what it touches

Computational design …usesMolecular structuresproducesResearch Triangle, No…located inTen63 Therapeut…

Each line is a relation with evidence behind it, drawn in the direction it points. A line shows that two things are connected, not how far this change reaches.

02

Evidence

  • PPR Newswire news releasesCompany2026-11-19 01:10
    Ten63 applies its computational design technology to generate and prioritize molecular structures against participant-nominated targets
    View source